Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multi-center, randomized, dose escalation study to document the
effects of adventitial delivery of temsirolimus (Torisel) after revascularization of lesions
below the knee in symptomatic patients with critical limb ischemia (CLI).